![Expert Opinion on Drug Discovery](/sites/default/files/styles/original_ratio_zero/public/2021-07/Expert%20Opinion%20on%20Drug%20Discovery.jpg?itok=b-apBiVN)
Connexin and pannexin (hemi)channels play an important role in paracrine and autocrine signaling pathways. The opening of these cellular pores is linked to a wide range of diseases. Therefore, pharmacological closing of connexin and pannexin (hemi)channels seems a promising therapeutic strategy. However, the currently available inhibitors cope with recurring problems concerning selectivity, specificity, stability and/or solubility.